Don Healey
About Don Healey
Don Healey, the Chief Technology Officer at Adicet since October 2020, has an extensive background in biopharmaceuticals, specializing in cellular therapies and immunology.
Don Healey - Chief Technology Officer at Adicet
Don Healey serves as the Chief Technology Officer at Adicet. He joined the company in October 2020. As CTO, he plays a crucial role in spearheading the company's technological advancements and overseeing its tech strategies. His appointment brought significant experience to the organization given his extensive background in the biopharmaceutical sector.
Don Healey's Role at KBI Biopharma Inc.
Before joining Adicet, Don Healey worked at KBI Biopharma Inc. At KBI, he was instrumental in establishing key aspects of the company's process development, manufacturing, quality control, and facilities management. His responsibilities included developing cellular therapies for biopharmaceutical clients, highlighting his expertise in advancing therapeutic processes.
Don Healey's Leadership at Opexa Therapeutics, Inc.
Don Healey served as the Chief Scientific Officer at Opexa Therapeutics, Inc. During his tenure, he oversaw all pre-clinical scientific development. Additionally, he managed the closed-system process design and facilitated the scaling of Opexa's autologous T-cell immunotherapy. His leadership was pivotal in driving Opexa's scientific and technological initiatives.
Don Healey's Experience in Immunology
Don Healey has a solid background in immunology, having served in various key positions. He was the Director of Immunology at Argos Therapeutics Inc. and a Group Leader for Immunology at ML Laboratories, UK (formerly Cobra Biotherapeutics). These roles underline his depth of experience and knowledge in the field of immunology.
Don Healey's Educational Background
Don Healey obtained his Ph.D. from the University of London, solidifying his expertise in the field. Prior to that, he completed his B.Sc. in Cellular Pathology at Bristol University. His academic background has provided a strong foundation for his career in biopharmaceuticals and immunology.